N-[(4-Methylphenyl)methyl]-2-[2-(trifluoromethyl)-1H-1,3-benzodiazol-1-yl]propanamide

Catalog No.: 
ACGDXT067
CAS No.: 
866144-31-2
Molecular Formula: 
C19H18F3N3O
Molecular Weight: 
361.37
N-[(4-Methylphenyl)methyl]-2-[2-(trifluoromethyl)-1H-1,3-benzodiazol-1-yl]propanamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg90%
1g90%
5g90%

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-[(4-Methylphenyl)methyl]-2-[2-(trifluoromethyl)-1H-1,3-benzodiazol-1-yl]propanamide
IUPAC NameN-(4-methylbenzyl)-2-(2-(trifluoromethyl)-1H-benzo[d]imidazol-1-yl)propanamide
Molecular FormulaC19H18F3N3O
Molecular Weight361.37
SMILESCC(N1C(C(F)(F)F)=NC2=CC=CC=C21)C(NCC3=CC=C(C)C=C3)=O
InChI KeyJXIIANWUOISDLF-UHFFFAOYSA-N
SynonymN-[(4-methylphenyl)methyl]-2-[2-(trifluoromethyl)-1H-1,3-benzodiazol-1-yl]propanamide;1H-Benzimidazole-1-acetamide, α-methyl-N-[(4-methylphenyl)methyl]-2-(trifluoromethyl)-
CAS No.866144-31-2

Synthetic Route by SureRoute

1. ACGDXT067 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACBAUS147 route compound structure diagram
    ACBAUS1472923-16-2In Stock
  4. Then
  5. ACGDXT067 route product structure diagram
    ACGDXT067866144-31-2
Inquiry

2. ACGDXT067 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGDXT067 route product structure diagram
    ACGDXT067866144-31-2
Inquiry

3. ACGDXT067 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGDXT067 route product structure diagram
    ACGDXT067866144-31-2
Inquiry

Comments (0)